Enhertu® (trastuzumab deruxtecan) – Expanded indication
January 27, 2025 - AstraZeneca and Daiichi Sankyo announced the FDA approval of Enhertu (trastuzumab deruxtecan), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Top